MA71260A - Méthodes de traitement d'un glioblastome avec des promédicaments de riluzole - Google Patents

Méthodes de traitement d'un glioblastome avec des promédicaments de riluzole

Info

Publication number
MA71260A
MA71260A MA71260A MA71260A MA71260A MA 71260 A MA71260 A MA 71260A MA 71260 A MA71260 A MA 71260A MA 71260 A MA71260 A MA 71260A MA 71260 A MA71260 A MA 71260A
Authority
MA
Morocco
Prior art keywords
methods
treating glioblastoma
riluzole prodrugs
riluzole
prodrugs
Prior art date
Application number
MA71260A
Other languages
English (en)
Inventor
Irfan QURESHI
Alissa RYBICKI
Katheryn GROSSMAN
Mary K. DONOHUE
Original Assignee
Biohaven Therapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd. filed Critical Biohaven Therapeutics Ltd.
Publication of MA71260A publication Critical patent/MA71260A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA71260A 2022-06-26 2023-06-26 Méthodes de traitement d'un glioblastome avec des promédicaments de riluzole MA71260A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263355631P 2022-06-26 2022-06-26
PCT/US2023/069038 WO2024006678A1 (fr) 2022-06-26 2023-06-26 Méthodes de traitement d'un glioblastome avec des promédicaments de riluzole
EP23832468.5A EP4543438A1 (fr) 2022-06-26 2023-06-26 Méthodes de traitement d'un glioblastome avec des promédicaments de riluzole

Publications (1)

Publication Number Publication Date
MA71260A true MA71260A (fr) 2025-04-30

Family

ID=89381658

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71260A MA71260A (fr) 2022-06-26 2023-06-26 Méthodes de traitement d'un glioblastome avec des promédicaments de riluzole

Country Status (10)

Country Link
EP (1) EP4543438A1 (fr)
JP (1) JP2025519970A (fr)
KR (1) KR20250036734A (fr)
CN (1) CN119816303A (fr)
AU (1) AU2023300980A1 (fr)
CA (1) CA3258423A1 (fr)
IL (1) IL317334A (fr)
MA (1) MA71260A (fr)
MX (1) MX2024015758A (fr)
WO (1) WO2024006678A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201908354VA (en) * 2015-03-03 2019-10-30 Biohaven Pharm Holding Co Ltd Riluzole prodrugs and their use
CN107530341B (zh) * 2015-03-06 2021-10-01 大连万春布林医药有限公司 治疗与ras突变相关的癌症的方法
CA2940470C (fr) * 2015-09-18 2019-08-20 Signpath Pharma Inc. Traitement de glioblastome
US20210308111A1 (en) * 2018-07-27 2021-10-07 With Great Power, Llc Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers

Also Published As

Publication number Publication date
AU2023300980A1 (en) 2025-01-09
KR20250036734A (ko) 2025-03-14
JP2025519970A (ja) 2025-06-26
CN119816303A (zh) 2025-04-11
WO2024006678A1 (fr) 2024-01-04
MX2024015758A (es) 2025-02-10
IL317334A (en) 2025-01-01
CA3258423A1 (fr) 2024-01-04
EP4543438A1 (fr) 2025-04-30

Similar Documents

Publication Publication Date Title
IL285662A (en) Use of cannabinoids in the treatment of epilepsy
EP3924481A4 (fr) Compositions et méthodes de traitement d&#39;hémoglobinopathies
MA46954A (fr) Méthodes de traitement d&#39;états inflammatoires
EP4087878A4 (fr) Complexes de ciblage musculaire et utilisations de ces derniers pour le traitement de dystrophinopathies
MA45985A (fr) Inhibiteurs de diacylglycérol acyltransférase 2
EP3991472A4 (fr) Traitement de problèmes en boucle de la mobilité conditionnelle
NZ631337A (en) Prodrugs of fumarates and their use in treating various diseases
MA43591A (fr) Méthodes d&#39;inhibition d&#39;une fibrose chez un sujet ayant besoin d&#39;un tel traitement
MA53329A (fr) Méthodes de traitement de l&#39;épilepsie
EP3307260A4 (fr) Dérivés de diaryl et arylhétéroaryl urée utiles pour la prophylaxie et le traitement du trouble du comportement en sommeil rem
MA54313A (fr) Méthodes de traitement d&#39;une maladie à l&#39;aide d&#39;inhibiteurs de magl
MA47504A (fr) Composés et méthodes de traitement de l&#39;angiocholite biliaire primitive
EP3927428A4 (fr) Méthodes de traitement d&#39;affections respiratoires
IL280177A (en) Use of riluzole prodrugs to treat Alzheimer&#39;s disease
EP4041312A4 (fr) Procédés de traitement d&#39;un trouble oculaire
EP3705182A4 (fr) Procédé de production d&#39;agent de traitement d&#39;eaux d&#39;égout à nano-catalyseur auto-adaptable
FR25C1007I1 (fr) Formulations d&#39;épinéphrine intranasale et méthodes de traitement d&#39;une maladie
EP3920898A4 (fr) Méthodes et compositions pour le traitement de l&#39;apnée du sommeil
EP3980540A4 (fr) Méthodes de traitement d&#39;une déficience en alpha-1 antitrypsine (aatd)
MA55209A (fr) Procédés de traitement de l&#39;amylose al
MA54827A (fr) Méthodes de traitement d&#39;une maladie à l&#39;aide d&#39;inhibiteurs de magl
EP3920940A4 (fr) Méthodes de prévention et de traitement d&#39;une inflammation et d&#39;une maladie inflammatoire
MA71260A (fr) Méthodes de traitement d&#39;un glioblastome avec des promédicaments de riluzole
EP3843746A4 (fr) Traitement du neuroblastome avec des produits d&#39;hydrolyse de taurolidine
EP4076669A4 (fr) Méthodes de traitement du glioblastome